Compare McDonald's Corp (MCD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? McDonald's Corp trades at $240.33 (market cap $166.87B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: McDonald's Corp is far larger — about 22.2× Spyre Therapeutics Inc. Common Stock's market cap, and McDonald's Corp pays a 3.27% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 165 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MCD | SYRE | |
|---|---|---|
Market Cap | $166.87B | $7.52B |
Volume | 4,543,119 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $108.92 |
52-Week Low | $230.88 | $22.18 |
Typical Hold Time | 165 Days | 0 Days |
Enterprise Value | $220.64B | $6.52B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $235.81, up 0.07% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth is steady, reaching $26.89B in 2025, while net income margin remains robust at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and menu innovation to drive growth.
The outlook is supported by analyst optimism with a consensus price target of $284.70, implying significant upside. However, risks include inflationary pressures on franchisee margins and high long-term debt of $38.42B. The stock presents a value opportunity with a P/E of 19.16, but investors should weigh execution risks against growth initiatives.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
